- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00563173
Phase I/IIa Dose Ranging CHRONVAC-C® Study in Chronic HCV Patients
February 9, 2010 updated by: Tripep AB
A Phase I/IIa Open-Label, Dose Ranging, Parallel, Safety, Tolerability and Efficacy Study of i.m. Administered CHRONVAC-C® in Combination With Electroporation in Chronic HCV Genotype 1 Infected and Treatment Naïve Patients With Low Viral Load
The purpose of this study is to evaluate if the DNA vaccine CHRONVAC-C® intended for future treatment of Hepatitis C infections is safe and tolerated when administered to HCV infected individuals with a low viral load.
In addition the capability of the vaccine to induce an immune response and the effect on viral load will be studied.
In order to increase the uptake of the vaccine the intra muscular injection is combined with electroporation, meaning that a brief electric field is applied to the injection site resulting in temporary pores in the cell membranes that allows the vaccine to enter the cells.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
12
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Stockholm, Sweden, SE-141 86
- I73 Department of Infectious Diseases, Karolinska Institute, Karolinska University Hospital, Huddinge
-
Stockholm, Sweden, SE-171 76
- Department of Gastroenterology and Hepatology, Karolinska University Hospital, Solna
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female patient 18 -65 years of age with a known chronic hepatitis C infection.
- Genotype 1 infection.
- Viral load equal to or less than 800.000 IU/mL.
- BMI less than 30.
- Considered probable that the deltoid muscles (left and right) of the patient will be reached at vaccination using a 12.7 mm cannula for injection and a 15 mm applicator tip for electroporation.
- Written informed consent obtained, and a copy provided to the patient.
- Patient legally competent and able to communicate effectively with the study personnel.
- Patient likely to co-operate and attend the clinic at the appointed times during the study.
Exclusion Criteria:
- Patient having clinically significant concomitant diseases other than HCV in the medical history to the discretion of the investigator.
- Patient having clinically significant findings on physical examination, vital signs, ECG or clinical laboratory evaluations to the discretion of the investigator.
- Patient having clinical or biochemical signs of cirrhosis.
- Positive hepatitis B surface antigen (HBsAg).
- Positive HIV antigen or antibody test.
- Patient having an ongoing and/or known viral infection other than HCV that requires treatment and/or special medical intention.
- Patient having received previous treatment for HCV.
- Radiation therapy or cytotoxic chemotherapeutic agents within 4 weeks prior to the first dose of study drug.
- Treatment with immunomodulating agents such as systemic corticosteroids, IL-2, IFN-alpha, IFN-beta, IFN-gamma within 4 weeks prior to the first dose of study drug.
- Treatment with NSAID within 10 days of the first dose of study drug.
- Immunization within 30 days of the first dose of the study drug.
- Patient having received an investigational drug product, or been enrolled in other investigational drug protocols within a period of 30 days prior to receiving the first dose of the study drug.
- Prior treatment with DNA therapy.
- Known allergy towards vaccines.
- Known abuse of alcohol, drugs or pharmaceuticals.
- History, signs or symptoms of a cardiac disease.
- Presence of an implantable pacemaker.
- Any metal implants within the treatment areas (close to the right and/or left deltoid muscles).
- Diagnoses of a serious psychiatric illness which may influence study participation.
- Female patient who is breast feeding.
- Female patient not clinically sterile (hysterectomy, tubal ligation or postmenopausal (amenorrhea > 1 year and FSH > 30 mU/ml) OR if not clinically sterile unwilling to use a reliable contraception method.
- Patient with a positive urine pregnancy test.
- Male patient unwilling to use condom for active prevention of pregnancy from first vaccination to 4 months after last injection.
- Patient or their immediate families being an investigator or site personnel directly affiliated with this study. Immediate family is defined as a spouse, parent, child or sibling, whether biologically or legally adopted.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: 1
Low dose
|
DNA vaccine, solution for injection, i.m. administration in combination with electroporation
|
Other: 2
Medium dose
|
DNA vaccine, solution for injection, i.m. administration in combination with electroporation
|
Other: 3
High dose
|
DNA vaccine, solution for injection, i.m. administration in combination with electroporation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate safety and tolerability of electroporation mediated i.m. delivery of CHRONVAC-C® in chronically HCV infected, treatment naive patients with low viral load.
Time Frame: From start of treatment to 24 weeks post treatment
|
From start of treatment to 24 weeks post treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To provide information regarding dose related anti-viral immune response and dose related effect on viral load.
Time Frame: From start of treatment to 24 weeks post treatment
|
From start of treatment to 24 weeks post treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Ola RH Weiland, Professor, I73 Department of Infectious Diseases, Karolinska Institute, Karolinska University Hospital, Huddinge, Sweden
- Study Chair: Anders Vahlne, Professor, Tripep AB
- Study Director: Matti Sällberg, Professor, Tripep AB
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2007
Primary Completion (Anticipated)
April 1, 2010
Study Completion (Anticipated)
April 1, 2010
Study Registration Dates
First Submitted
November 23, 2007
First Submitted That Met QC Criteria
November 23, 2007
First Posted (Estimate)
November 26, 2007
Study Record Updates
Last Update Posted (Estimate)
February 10, 2010
Last Update Submitted That Met QC Criteria
February 9, 2010
Last Verified
February 1, 2010
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CVC-201
- EudraCT No. 2007-002901-33
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Hepatitis C Virus Infection
-
University Health Network, TorontoCompletedChronic Hepatitis C Virus InfectionCanada
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsWithdrawnChronic Hepatitis C Virus InfectionIsrael
-
Hadassah Medical OrganizationUnknownChronic Hepatitis C Virus InfectionIsrael
-
PharmaEssentiaCompletedChronic Hepatitis C Virus InfectionKorea, Republic of, Taiwan, China
-
Beni-Suef UniversityCompletedChronic Hepatitis C Virus InfectionEgypt
-
Vertex Pharmaceuticals IncorporatedTerminatedChronic Hepatitis C Virus InfectionUnited States, New Zealand
-
Bristol-Myers SquibbCompletedChronic Hepatitis C Virus Infection | Chronic Hepatitis B Virus InfectionUnited States
-
Humanity and Health Research CentreBeijing 302 HospitalCompletedChronic Hepatitis C InfectionChina
-
Gilead SciencesCompleted
-
AbbVieCompleted
Clinical Trials on CHRONVAC-C®
-
ChronTech Pharma ABInovio PharmaceuticalsUnknownChronic Hepatitis CSweden
-
Cardica, IncCompletedHeart DiseaseUnited States
-
Centre Hospitalier Universitaire VaudoisB. Braun Melsungen AGCompletedShoulder Pain | Regional Anesthesia Morbidity | Shoulder ArthritisSwitzerland
-
Nuwellis, Inc.Terminated
-
NGMedical GmbHRecruitingRadiculopathy | Stenoses, Spinal | Discopathy | Herniated Cervical DiscAustria, Germany
-
MicroPort Orthopedics Inc.Enrolling by invitationJoint DiseaseGermany
-
Hospital General Universitario de ValenciaFIPSERecruitingDifficult Intubation | Anesthesia Intubation ComplicationSpain
-
SanofiCompletedMeningitis | Meningococcal Infections | Meningococcal MeningitisUnited States
-
Merck Sharp & Dohme LLCCompletedMeningitis, Meningococcal | Rotavirus Infections
-
Sanofi Pasteur, a Sanofi CompanyCompletedMeningitis | Meningococcal InfectionsUnited States